Indoco Remedies Shares Surge 18% Following Positive UK-MHRA Inspection at Goa Facility and Strong Q1FY27 Financial Turnaround

• by Akanksha Mishra
• 2026-09-10 16:40:00

Shares of pharmaceutical major Indoco Remedies experienced a massive upward surge on Thursday, climbing nearly 18 percent intraday after the company announced a successful regulatory clearance from the United Kingdom Medicines and Healthcare Products Regulatory Agency (UK-MHRA) for its manufacturing plant in Goa. The stock rallied sharply to an intraday high of Rs 269.90 from a low of Rs 229, trading strongly on the National Stock Exchange as market participants welcomed the positive compliance update. The inspection, conducted between September 7 and September 9 at the company's Solid Dosage Manufacturing Facility at Goa Plant I, concluded with zero critical or major observations under Current Good Manufacturing Practices (cGMP) standards.

Strategic Importance of Goa Plant I and Global Export Markets

The regulatory clean chit is a significant milestone for Indoco Remedies, given that Goa Plant I serves as a vital export hub supplying regulated international markets across the United Kingdom, Europe, South Africa, New Zealand, Australia, and Canada. According to corporate disclosures, this specific facility accounts for roughly 30 percent of the company's total international business revenue. Managing Director Aditi Panandikar lauded the achievement, emphasizing that the flawless inspection report highlights the firm's unyielding commitment to world-class quality standards and rigorous manufacturing protocols. Despite facing a minor regulatory hurdle earlier in the week—where the US Food and Drug Administration (USFDA) issued seven observations in Form 483 following an inspection of the company's Plant II (Sterile) facility in Goa—the UK-MHRA clearance has successfully restored positive sentiment.

Strong Financial Recovery and Impressive Q1FY27 Margins

The stellar stock performance is further underpinned by a dramatic financial turnaround reported in the company's June quarter earnings for Q1FY27. Indoco Remedies bounced back strongly to post a net profit of Rs 65 crore, reversing a net loss of Rs 36 crore recorded in the corresponding quarter of the previous fiscal year. Operational revenue grew by 6.4 percent year-on-year to reach Rs 467 crore compared to Rs 439 crore previously. Concurrently, the company's operating performance witnessed sharp margin expansion, with EBITDA surging to Rs 40.8 crore from Rs 16.7 crore, driving the EBITDA margin up to 8.7 percent from 3.8 percent a year ago and delivering a robust 34 percent return to investors over the past six months.

Previous Post

Safe, Secure, and Guaranteed: Why Post Office RD is Toppling Market Investments in 2026

Next Post

LCC Projects IPO GMP Surges as Issue Achieves Full Subscription on Day Two, Signaling Up to 34 Percent Listing Gains